NYSE:PRME Prime Medicine (PRME) Stock Price, News & Analysis $3.99 -0.47 (-10.54%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends About Prime Medicine Stock (NYSE:PRME) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prime Medicine alerts:Sign Up Key Stats Today's Range$3.93▼$4.4850-Day Range$3.41▼$4.5352-Week Range$3.28▼$9.86Volume1.20 million shsAverage Volume982,090 shsMarket Capitalization$478.92 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingModerate Buy Company OverviewPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Prime Medicine Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScorePRME MarketRank™: Prime Medicine scored higher than 56% of companies evaluated by MarketBeat, and ranked 447th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePrime Medicine has only been the subject of 2 research reports in the past 90 days.Read more about Prime Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($1.75) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prime Medicine's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PRME. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth.Read more about Prime Medicine's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for PRME. News and Social Media1.9 / 5News Sentiment0.46 News SentimentPrime Medicine has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search Interest5 people have searched for PRME on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have not sold or bought any company stock.Percentage Held by Insiders24.29% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address PRME Stock News HeadlinesPrime Medicine, Inc. (NYSE:PRME) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 22 at 4:45 AM | americanbankingnews.comWhy I Keep Buying These 14 Incredible Growth StocksOctober 16, 2024 | fool.comTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…October 24, 2024 | Timothy Sykes (Ad)Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific MeetingsOctober 15, 2024 | finance.yahoo.comPrime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific MeetingsOctober 15, 2024 | globenewswire.comPrime Medicine, Inc. (PRME) Receives a Hold from Morgan StanleyOctober 12, 2024 | markets.businessinsider.comPrime Medicine’s Strategic Alliances and Growth Potential Affirm Buy RatingOctober 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine on Strategic Partnerships and Technology Platform PotentialOctober 2, 2024 | markets.businessinsider.comSee More Headlines PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $8.86 on January 1st, 2024. Since then, PRME shares have decreased by 55.0% and is now trading at $3.99. View the best growth stocks for 2024 here. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NYSE:PRME) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.06. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an initial public offering (IPO) on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share. Who are Prime Medicine's major shareholders? Top institutional shareholders of Prime Medicine include SG Americas Securities LLC (0.04%) and IQ EQ FUND MANAGEMENT IRELAND Ltd (0.02%). Insiders that own company stock include Robert Nelsen and 2019 Gp LLC Gv. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Prime Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Intel (INTC), NVIDIA (NVDA), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/08/2024Today10/24/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:PRME CUSIPN/A CIK1894562 Webprimemedicine.com Phone617-564-0013FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+238.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,130,000.00 Net MarginsN/A Pretax Margin-36,809.98% Return on Equity-106.30% Return on Assets-81.24% Debt Debt-to-Equity RatioN/A Current Ratio8.23 Quick Ratio8.23 Sales & Book Value Annual Sales$591,000.00 Price / Sales810.36 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book2.91Miscellaneous Outstanding Shares120,031,000Free Float91,860,000Market Cap$478.92 million OptionableOptionable Beta2.18 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NYSE:PRME) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredAmerica’s Election NightmareThanks to a new law signed by President Biden, a small group of powerful people could decide who is installed ...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.